Treatment options in HBV

Journal of Hepatology

Volumn 44, Issue SUPPL. 1, 2006, Pages

  Craxì, Antonio ^a   Antonucci, Giorgio ^b   Cammà, Calogero ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Adefovir; Hepatitis B; HIV; Interferon; Lamivudine; Liver disease; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; GUANINE DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PLACEBO; PYRIMIDINE NUCLEOSIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DEATH; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HUMANS; TREATMENT OUTCOME;

EID: 30144444548     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.11.018     Document Type: Conference Paper

References (71)

1. D.K. Wong, A.M. Cheung, K. O'Rourke, C.D. Naylor, A.S. Detsky, and J. Heathcote Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 119 1993 312 323
2. P. Almasio, C. Cammà, M. Giunta, and A. Craxì Treatment of chronic hepatitis B: an evidence-based review J.W.D. McDonald A. Burroughs B.G. Feagan Evidence-based gastroenterology and hepatology 1999 BMJ publ London 305 321
3. A. Craxì, D. Di Bona, and C. Cammà Interferon-α for HBeAg-positive chronic hepatitis B J Hepatol 39 2003 S99 S105
4. F. Tiné, A. Liberati, A. Craxì, P. Almasio, and L. Pagliaro Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature J Hepatol 18 1993 154 162
5. G. Pastore, T. Santantonio, M. Milella, L. Monno, N. Mariano, and R. Moschetta Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon J Hepatol 14 1992 221 225
6. S. Hadziyannis, T. Bramou, A. Makris, G. Moussoulis, L. Zignego, and C. Papaioannou Interferon alpha-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B J Hepatol 11 1990 S133 S136
7. G. Fattovich, P. Farci, M. Rugge, L. Brollo, A. Mandas, and P. Pontisso A randomized controlled trial of lymphoblastoid interferon-a in patients with chronic hepatitis B lacking HBeAg Hepatology 15 1992 584 589
8. M.R. Brunetto, M. Giarin, G. Saracco, F. Olivieri, P. Calvo, and G. Capra Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B Gastroenterology 105 1993 845 850
9. P. Lampertico, E. Del Ninno, A. Manzin, M.F. Donato, M.G. Rumi, and G. Lunghi A randomized, controlled trial of a 24-month course of interferon alpha 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum Hepatology 26 1997 1621 1625
10. F. Oliveri, T. Santantonio, G. Bellati, P. Colombatto, G.C. Mels, and L. Carriero Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon Am J Gastroenterol 94 1999 1366 1372
11. J.M. Lopez-Alchorocho, J. Bartolome, T. Cotonat, and V. Carreno Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HbeAb: comparison between 6 and 12 months of therapy J Viral Hepat 4 1997 27 32
12. P. Lampertico, E. Del Ninno, M. Vigano, R. Romeo, M.F. Donato, and E. Sablon Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 2003 756 763
13. G.V. Papatheodoridis, E. Manesis, and S.J. Hadziyannis Long term outcome of interferon-alpha treated and untreated patients with HBeAg negative chronic hepatitis B J Hepatol 34 2000 306 313
14. E. Manesis, and S. Hadziyannis Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B Gastroenterology 121 2001 101 109
15. M.R. Brunetto, F. Oliveri, B. Coco, G. Leandro, P. Colombatto, and J.M. Gorin Outcome of ant i-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study Hepatology 36 2002 263 270
16. C. Cammà, M. Giunta, P. Andreone, and A. Craxì Interferon and prevention of hepatocellular carcinoma: an evidence-based approach J Hepatol 34 2001 593 602
17. Y. Benhamou, E. Dohin, F. Lunel-Fabiani, T. Poynard, J.M. Huraux, and C. Katlama Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients Lancet 345 1995 396 397
18. Y. Benhamou, C. Katlama, F. Lunel, A. Coutellier, E. Dohin, and N. Hamm Effects of lamivudine on replication of hepatitis B virus in HIV-infected men Ann Intern Med 125 1996 705 712
19. F. Nevens, J. Main, P. Honkoop, D.L. Turrell, J. Barber, and M.T. Sullivan Lamivudine therapy for chronic hepatitis B: a six- month randomized dose-ranging study Gastroenterology 113 1997 1258 1263
20. C.L. Lai, C.K. Ching, A.K.M. Tung, E. Li, J. Young, and A. Hill Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial Hepatology 25 1997 241 244
21. C.L. Lai, R.N. Chien, N.W.Y. Leung, T.T. Chang, R. Guan, and D.I. Tai And Asia hepatitis lamivudine study group. A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 1998 61 68
22. J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W. Hann, and Z. Goodman Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 21 341 1999 1256 1263
23. S.W. Schalm, J. Heathcote, J. Cianciara, G. Farrell, M. Sherman, and B. Willems Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial Gut 46 2000 562 568
24. N.C. Tassopoulos, R. Volpes, G. Pastore, J. Heathcote, M. Buti, and R.D. Goldin Efficacy of lamivudine in patients with hepatitis B eantigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant study group Hepatology 29 1999 889 896
25. A.B. Van Nunen, B.E. Hansen, D.J. Suh, H.F. Lohr, L. Chemello, and H. Fontaine Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase Gut 52 2003 420 424
26. K.M. Lee, S.W. Cho, S.W. Kim, H.J. Kim, K.B. Hahm, and J.H. Kim Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion J Viral Hepat 9 2002 208 212
27. B.C. Song, D.J. Suh, H.C. Lee, Y.H. Chung, and Y.S. Lee Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
28. J.L. Dienstag, J. Cianciara, S. Karayalcin, K.V. Kowdley, B. Willems, and S. Plisek Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 37 2003 748 755
29. G.V. Papatheodoridis, E. Dimou, A. Laras, V. Papadimitropoulos, and S.J. Hadziyannis Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease Hepatology 36 2002 219 226
30. G. Barbaro, F. Zechini, A.M. Pellicelli, R. Francavilla, G. Scotto, and D. Bacca Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial J Hepatol 35 2001 406 411
31. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu HBV 99-01 study group; Rotterdam foundation for liver research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
32. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, and R. Jin Peginterferon Alfa-2a HBeAg-negative chronic hepatitis B study group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
33. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, and H. Yuen For cirrhosis asian lamivudine multicentre study group. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
34. V. Di Marco, A. Marzano, P. Lampertico, P. Andreone, T. Santantonio, and P.L. Almasio Italian association for the study of the liver (AISF) lamivudine study group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine Hepatology 40 2004 883 891
35. P. Marcellin, T.T. Chang, S.G. Lim, M.J. Tong, W. Sievert, and M.L. Shiffman Adefovir dipivoxyl for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 27 348 2003 808 816
36. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, and M. Rizzetto Adefovir dipivoxyl for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
37. R. Gish, N. Leug, C. Wang, L. Corey, S. Sacks, and M. Fried Antiviral activity, safety and incidence of resistance in chronically infected hepatitis B patients (CHB) given once a daily emtricitabine for 2 years Hepatology 36 2002 372A
38. Shiffman MLA, Ng TM, Krastev Z, Kotzev IA, Mechkov G, Kung NNS, et al. A double-blind, placebo, controlled trial of emtricitabine (FTC, Emtriva) administered once-daily for treatment of chronic hepatitis B virus (HBV) infection. Hepatology 2004; 40(Suppl.):22A.
39. F. van Bommel, T. Wunsche, S. Mauss, P. Reinke, A. Bergk, and D. Schurmann Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection Hepatology 40 2004 1421 1425
40. S.K. Ono, N. Kato, Y. Shiratori, J. Kato, T. Goto, and R.F. Schinazi The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance J Clin Invest 107 2001 449 455
41. Chang TT, Gish R, de Man R, Gadano A, Sollano J, Han KH, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of a phase III study ETV-022 in nucleoside naive patients. Hepatology 2004; 40(Suppl.):70A.
42. Shouval D, Ching-Lung Lai Cheinquer H, Lok A, DeHertogh D, Wilber R, et al. Entecavir demonstrates superior histologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: results of phase III trial ETV-027. Hepatology 2004; 40(Suppl.):07A.
43. B. Seigneres, C. Pichoud, P. Martin, P. Furman, C. Trepo, and F. Zoulim Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses Hepatology 36 2002 710 722
44. P. Marcellin, H. Mommeja-Marin, S. Sacks, G. Lau, D. Sereni, and J. Bronowicki A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B Hepatology 40 2004 140 148
45. Lee KS, Byun KS, Chung YH, Paik SW, Han J, Yoo K, et al. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12-week clevudine therapy. Hepatology 2004; 40(Suppl.):1138A.
46. M.L. Bryant, E.G. Bridges, L. Placidi, A. Faraj, A.G. Loi, and C. Pierra Antiviral L-nucleosides specific for hepatitis B virus infection Antimicrob Agents Chemother 45 2001 229 235
47. A.S. Lok New treatment of chronic hepatitis B Semin Liver Dis 24 Suppl. 1 2004 77 82
48. C.L. Lai, S.G. Lim, N.A. Brown, X.J. Zhou, D.M. Lloyd, and Y.M. Lee A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection Hepatology 40 2004 719 726
49. Lai C, Leung NWL, Teo E, Tong M, Wong F, Hann H, et al. Results of a one-year international phase-IIb comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology 2004; 40(Suppl.):219A.
50. J.A. McDonald, L. Caruso, P. Karayiannis, L.J. Scully, J.R. Harris, and G.E. Forster Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon Hepatology 7 1987 719 723
51. J.H. Hoofnagle, M. Peters, K.D. Mullen, D.B. Jones, V. Rustgi, and A. Di Bisceglie Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B Gastroenterology 95 1988 1318 1325
52. M.G. Brook, J.A. McDonald, P. Karayiannis, L. Caruso, G. Forster, and J.R. Harris Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response Gut 30 1989 1116 1122
53. M.G. Brook, G. Chan, I. Yap, P. Karayiannis, A.M. Lever, and M. Jacyna Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection Br Med J 299 1989 652 656
54. S. Pol, J. Jiang, and F. Driss Efficacy of interferon.alpha in chronic active hepatitis B infection J Hepatol 16 1992 20
55. D.K. Wong, C. Yim, C.D. Naylor, E. Chen, M. Sherman, and S. Vas Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population Gastroenterology 108 1995 165 171
56. H. Zylberberg, J. Jiang, G. Pialoux, F. Driss, F. Carnot, and F. Dubois Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients Gastroenterol Clin Biol 20 1996 968 971
57. V. Di Martino, T. Thevenot, J.F. Colin, N. Boyer, M. Martinot, and F. Degos Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B Gastroenterology 123 2002 1812 1822
58. The CAESAR Coordinating Committee Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial Lancet 349 1997 1413 1421
59. G.J. Dore, D.A. Cooper, C. Barrett, L.E. Goh, B. Thakrar, and M. Atkins Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-co-infected persons in a randomized, controlled study (CAESAR). The CAESAR coordinating committee J Infect Dis 180 1999 607 613
60. V. Thibault, Y. Benhamou, C. Seguret, M. Bochet, C. Katlama, and F. Bricaire Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients co-infected with HBV and human immunodeficiency virus J Clin Microbiol 37 1999 3013 3016
61. L.M. Wolters, H.G. Niesters, B.E. Hansen, M.E. van der Ende, F.P. Kroon, and C. Richter Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort J Clin Virol 24 2002 173 181
62. R. Bruno, P. Sacchi, A. Malfitano, and G. Filice YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient Gastroenterology 121 2001 1027 1028
63. D. Neau, E. Schvoerer, D. Robert, F. Dubois, H. Dutronc, and H.J. Fleury Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient J Infect 41 2000 192 194
64. Y. Benhamou, M. Bochet, V. Thibault, V. Calvez, M.H. Fievet, and P. Vig Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study Lancet 358 2001 718 723
65. Benhamou Y, Thibault V, Vig P, Valantin MA, Guyon P, Katlama C, Long term treatment with adefovir dipivoxil 10 mg (ADV) in patients with lamivudine-resistant (LAM-R) HBV and HIV co-infection results in significant and sustained clinical improvement, XV Int AIDS Conf, Bangkok, 11-16 June 2004; [Abstract WeOrA1329].
66. C. Delaugerre, A.G. Marcelin, V. Thibault, G. Peytavin, T. Bombled, and M.V. Bochet Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-co-infected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine Antimicrob Agents Chemother 46 2002 1586 1588
67. Y. Benhamou, R. Tubiana, and V. Thibault Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus N Engl J Med 348 2003 177 178
68. M. Nelson, S. Portsmouth, J. Stebbing, M. Atkins, A. Barr, and G. Matthews An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals AIDS 17 2003 F7 F10
69. Gilleece Y, Nelson M, Clarke A, Fischer M, Bower M, Atkins M, et al. Tenofovir in the treatment of Hepatitis B/HIV co-infected individuals XV Int AIDS Conference, Bangkok, 11-16 June 2004; [Abstract MoPeB3298].
70. G.J. Dore, D.A. Cooper, A.L. Pozniak, E. DeJesus, L. Zhong, and M.D. Miller For 903 study team; 907 study team. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients co-infected with HIV-1 and hepatitis B virus J Infect Dis 189 2004 1185 1192
71. F. Bani-Sadr, P. Palmer, C. Scieux, and J.M. Molina Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients co-infected with HIV-1 and wild-type hepatitis B virus Clin Infect Dis 39 2004 1062 1064